Clinical Trial Update: Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing fludarabine, pixantrone, and rituximab versus fludarabine and rituximab for relapsed or refractory indolent non-Hodgkin's lymphoma was…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Fludarabine (Fludarabine)
• Pixantrone (pixantrone)
• Rituximab (rituximab)

Snippet

Sponsor: CTI BioPharma | Conditions: Non-Hodgkin's Lymphoma | Phase 3 | Status: WITHDRAWN